CA3125625A1 - Inhibitors of cgas activity as therapeutic agents - Google Patents
Inhibitors of cgas activity as therapeutic agents Download PDFInfo
- Publication number
- CA3125625A1 CA3125625A1 CA3125625A CA3125625A CA3125625A1 CA 3125625 A1 CA3125625 A1 CA 3125625A1 CA 3125625 A CA3125625 A CA 3125625A CA 3125625 A CA3125625 A CA 3125625A CA 3125625 A1 CA3125625 A1 CA 3125625A1
- Authority
- CA
- Canada
- Prior art keywords
- pyrimidin
- methylbenzofuro
- carboxylic acid
- compound
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962788624P | 2019-01-04 | 2019-01-04 | |
| US62/788,624 | 2019-01-04 | ||
| PCT/US2020/012243 WO2020142729A1 (en) | 2019-01-04 | 2020-01-03 | Inhibitors of cgas activity as therapeutic agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3125625A1 true CA3125625A1 (en) | 2020-07-09 |
Family
ID=72338800
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3125625A Pending CA3125625A1 (en) | 2019-01-04 | 2020-01-03 | Inhibitors of cgas activity as therapeutic agents |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220073532A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3906241A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7507161B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20210112316A (cg-RX-API-DMAC7.html) |
| CN (1) | CN113302194A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020205114A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3125625A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020142729A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4216940A4 (en) * | 2020-09-24 | 2025-01-01 | Ventus Therapeutics U.S., Inc. | PYRIDO[4,3-B INDOLE DERIVATIVES AND THEIR USE AS MEDICAMENTS |
| CN116997339A (zh) * | 2021-02-11 | 2023-11-03 | 贝尔布鲁克实验室有限责任公司 | 作为治疗剂的cGAS活性抑制剂 |
| BR112023020381A2 (pt) | 2021-05-12 | 2023-11-21 | Boehringer Ingelheim Int | Derivados de piridina com substituintes cíclicos ligados por c como inibidores de cgas |
| CN117337292A (zh) * | 2021-05-12 | 2024-01-02 | 勃林格殷格翰国际有限公司 | 作为cGAS抑制剂的具有N-连接环状取代基的吡啶衍生物 |
| CN117337291A (zh) * | 2021-05-12 | 2024-01-02 | 勃林格殷格翰国际有限公司 | 作为cGAS抑制剂的具有C-连接环状取代基的吡啶衍生物 |
| WO2024035622A1 (en) * | 2022-08-10 | 2024-02-15 | Bellbrook Labs, Llc | INHIBITORS OF cGAS ACTIVITY AS THERAPEUTIC AGENTS |
| CA3267076A1 (en) * | 2022-11-09 | 2024-05-16 | Boehringer Ingelheim International Gmbh | CYCLIC PYRIDINE DERIVATIVES USED AS CGAS INHIBITORS |
| CN121248633A (zh) * | 2022-11-09 | 2026-01-02 | 勃林格殷格翰国际有限公司 | 作为cGAS抑制剂的环状苯并咪唑衍生物 |
| US20250257076A1 (en) | 2024-02-14 | 2025-08-14 | Janssen Pharmaceutica Nv | SUBSTITUTED PYRROLIDINE-2-CARBOXYLIC ACID DERIVATIVES AS cGAS INHIBITORS |
| WO2025233174A1 (en) | 2024-05-08 | 2025-11-13 | Boehringer Ingelheim International Gmbh | Benzimidazole derivatives as cgas inhibitors |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3755583A (en) * | 1970-06-05 | 1973-08-28 | Chas0!nhx | |
| DE10348023A1 (de) * | 2003-10-15 | 2005-05-19 | Imtm Gmbh | Neue Alanyl-Aminopeptidasen-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen |
| EP1812113A1 (en) * | 2004-11-11 | 2007-08-01 | Argenta Discovery Limited | Pyrimidine compounds as histamine modulators |
| EP1767537A1 (en) | 2005-09-21 | 2007-03-28 | Cellzome (UK) Ltd. | Pyrimidine compounds for the treatment of inflammatory disorders |
| ES2441958T3 (es) * | 2006-07-11 | 2014-02-07 | Janssen Pharmaceutica Nv | Moduladores de benzofuro- y benzotienopirimidina del receptor de histamina H4 |
| AU2008345225A1 (en) * | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| GB2465405A (en) * | 2008-11-10 | 2010-05-19 | Univ Basel | Triazine, pyrimidine and pyridine analogues and their use in therapy |
| WO2013115167A1 (ja) | 2012-01-31 | 2013-08-08 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | アムバチニブ誘導体 |
| CN104513258B (zh) * | 2013-09-26 | 2018-04-03 | 广东东阳光药业有限公司 | 取代脲衍生物及其在药物中的应用 |
| KR20250065420A (ko) * | 2015-12-25 | 2025-05-12 | 가부시키가이샤 한도오따이 에네루기 켄큐쇼 | 화합물, 발광 소자, 표시 장치, 전자 기기, 및 조명 장치 |
| EP3700527A4 (en) * | 2017-10-25 | 2021-03-10 | Children's Medical Center Corporation | PAPD5 INHIBITORS AND METHOD OF USING THEM |
-
2020
- 2020-01-03 WO PCT/US2020/012243 patent/WO2020142729A1/en not_active Ceased
- 2020-01-03 CA CA3125625A patent/CA3125625A1/en active Pending
- 2020-01-03 KR KR1020217020729A patent/KR20210112316A/ko not_active Withdrawn
- 2020-01-03 JP JP2021539166A patent/JP7507161B2/ja active Active
- 2020-01-03 US US17/419,833 patent/US20220073532A1/en not_active Abandoned
- 2020-01-03 EP EP20736080.1A patent/EP3906241A4/en not_active Withdrawn
- 2020-01-03 CN CN202080007945.XA patent/CN113302194A/zh active Pending
- 2020-01-03 AU AU2020205114A patent/AU2020205114A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022518148A (ja) | 2022-03-14 |
| JP7507161B2 (ja) | 2024-06-27 |
| EP3906241A4 (en) | 2022-11-02 |
| EP3906241A1 (en) | 2021-11-10 |
| US20220073532A1 (en) | 2022-03-10 |
| WO2020142729A1 (en) | 2020-07-09 |
| KR20210112316A (ko) | 2021-09-14 |
| AU2020205114A1 (en) | 2021-07-22 |
| CN113302194A (zh) | 2021-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7507161B2 (ja) | 治療薬としてのcGAS活性の阻害剤 | |
| US20230219926A1 (en) | Substituted carboxamides as inhibitors of wdr5 protein-protein binding | |
| ES2866152T3 (es) | Derivados de tirosina amida como inhibidores de la Rho-quinasa | |
| JP6759514B2 (ja) | ブロモドメインに対して活性な化合物 | |
| JP7507162B2 (ja) | 治療薬としてのcGAS活性の阻害剤 | |
| EP3354640A2 (en) | Mif inhibitors and their uses | |
| TW202016094A (zh) | 週期素依賴性激酶抑制劑 | |
| US20190119264A1 (en) | Inhibitors of wdr5 protein-protein binding | |
| US20180222904A1 (en) | Bruton's tyrosine kinase inhibitors | |
| US20210284635A1 (en) | Novel naphthyridinone derivatives and their use in the treatment of arrhythmia | |
| JP2010523530A (ja) | タンパク質キナーゼ阻害剤として有益な[2,6]ナフチリジン | |
| CA3206520A1 (en) | Inhibitors of cgas activity as therapeutic agents | |
| WO2017114448A1 (zh) | 磺酰胺衍生物及其制备方法与应用 | |
| TW202448435A (zh) | 經取代之噻二唑基化合物 | |
| EP4263547B1 (en) | Dihydrofuropyridine derivatives as rho- kinase inhibitors | |
| US20230278996A1 (en) | Ykl-40 inhibitors and their therapeutic applications | |
| TW201441193A (zh) | 吡啶酮化合物 | |
| JP2025528113A (ja) | 治療剤としてのcGAS活性の阻害剤 | |
| CN121895236A (zh) | 一种itk激酶选择性抑制剂及其应用 | |
| EP4263549A1 (en) | Dihydrofuropyridine derivatives as rho-kinase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220926 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250902 |
|
| U13 | Renewal or maintenance fee not paid |
Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE Effective date: 20251103 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260102 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260216 |